source
- SK Biopharma signs $795 million licensing deal with Biohaven for epilepsy therapy opakalimSK Biopharma has entered a licensing agreement with Biohaven Pharmaceuticals to acquire worldwide rights to the Kv7 ion channel activator opakalim (BHV-7000) for epilepsy. The deal provides an upf…
- Vitruvias Therapeutics shuts down after recalling potentially superpotent thyroid tabletsVitruvias Therapeutics announced it is ceasing operations and has voluntarily recalled a batch of its generic thyroid tablets because the product may be superpotent. The recall covers 3,655 units…